Stem-cell exhaustion, read in the blood: what clonal haematopoiesis reveals
As blood stem cells age, mutant clones take over. By the eighth decade this shows up in about one person in ten — and it tracks with higher mortality and heart disease.
| Group | Value (%) |
|---|---|
| 70–79 years | 9.5 |
| 80–89 years | 11.7 |
| 90–108 years | 18.4 |
Stem-cell exhaustion — the age-related decline in the pool of cells that replenish tissues — is one of the recognised hallmarks of ageing, and blood is the place it can be measured most directly [s3]. As the blood-forming stem cells accumulate mutations over a lifetime, one mutant lineage can gain an edge and quietly expand, a state called clonal haematopoiesis. It is rare before 40 and becomes common with age: in one large study it was detectable in 9.5% of people aged 70 to 79, 11.7% of those 80 to 89, and 18.4% of those aged 90 to 108 [s1]. And it is not benign background noise — it tracks with worse survival and, unexpectedly, with heart disease.
From a hallmark to a number
The "hallmarks of ageing" framework groups the biology of getting old into interacting processes, and stem-cell exhaustion sits among them: the machinery that regenerates blood, gut lining and other tissues loses capacity, which shows up as anaemia, weakened immunity and slower repair [s3]. What makes the blood system special is that a tube of blood can be sequenced, so the abstract idea of an ageing stem-cell compartment becomes a countable event — a specific mutation carried by a measurable fraction of a person's blood cells.
That is what clonal haematopoiesis of indeterminate potential, or CHIP, describes: a detectable, expanded clone driven by a mutation in a gene such as DNMT3A, TET2, ASXL1 or JAK2, in someone with otherwise normal blood counts and no leukaemia [s2]. "Indeterminate potential" is the honest part of the name — most carriers never develop a blood cancer, though their risk is elevated.
What the clones predict
The reason CHIP is more than a curiosity is what it forecasts. In the 2014 study, carriers had a higher rate of death from any cause (hazard ratio 1.4, 95% CI 1.1–1.8) over the following years [s1]. More surprising was where the excess risk showed up: coronary heart disease (hazard ratio 2.0, 95% CI 1.2–3.4) and ischaemic stroke (hazard ratio 2.6, 95% CI 1.4–4.8) [s1]. A mutation in blood stem cells was predicting heart attacks, not just leukaemia.
A 2017 study nailed that link down. Pooling prospective cohorts, it found CHIP carriers had a risk of coronary heart disease 1.9 times as great (95% CI, 1.4–2.7), and in cohorts of early-onset heart attack the risk of myocardial infarction was 4.0 times as great (95% CI, 2.4–6.7) [s2]. Mutations in DNMT3A, TET2, ASXL1 and JAK2 were each individually associated with coronary disease, and CHIP carriers had more coronary-artery calcification [s2]. In mice, engineering the same Tet2 mutation accelerated atherosclerosis and raised inflammatory gene expression in the immune cells that build arterial plaque [s2] — a plausible mechanism in which ageing, mutant white cells inflame the artery wall.
What it means, and what it doesn't
CHIP is best understood as a readout of an ageing stem-cell system, and a marker of risk, rather than a diagnosis or a target with a proven fix. There is no established treatment that erases a clone or that has been shown, in a trial, to reduce the associated heart risk; the human evidence so far is observational and mechanistic, strong on association but not yet on intervention [s2]. That distinction matters because commercial tests for clonal mutations already exist, and a positive result today mostly buys anxiety without an action.
The wider interest is what CHIP says about how ageing works. It ties stem-cell exhaustion to chronic inflammation and connects to cellular senescence as another way that a few misbehaving cells drive system-wide risk — the same theme that runs through the hallmarks-of-ageing framework. What to watch is whether the inflammatory pathway identified in the mouse work becomes a genuine target in people, which would turn a risk marker into something a reader could actually act on.
Sources
- [s1] Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes — New England Journal of Medicine (2014). https://doi.org/10.1056/NEJMoa1408617
- [s2] Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease — New England Journal of Medicine (2017). https://doi.org/10.1056/NEJMoa1701719
- [s3] Hallmarks of aging: An expanding universe — Cell (2023). https://doi.org/10.1016/j.cell.2022.11.001
Sources
- Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes — The New England Journal of Medicine , November 26, 2014
- Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease — The New England Journal of Medicine , June 21, 2017
- Hallmarks of aging: An expanding universe — Cell , January 19, 2023
Clearing worn-out 'senescent' cells rejuvenates mice. In humans the trials are tiny
Cellular senescence is a well-evidenced driver of ageing in animals. The first human trials of senolytic drugs that clear these cells are real but tiny, early, and nowhere near proving longer healthy life.
Frequent sauna use tracks with longer life. No trial has shown it causes it
Finnish cohorts link regular sauna bathing to lower cardiovascular and all-cause mortality, with a dose-response. But these are observational studies, and no randomised trial has tested sauna against death.
GDF11 was called young blood's rejuvenation factor. A rival lab could not reproduce it.
Mouse studies claimed one circulating protein reversed ageing of the heart, muscle and brain. A second team found the muscle effect ran the opposite way — and no human trial has ever tested it.
Is sitting shortening your life? In a million people, enough activity cancelled the risk.
A harmonised meta-analysis of over a million adults found high sitting time raised mortality — but about 60 to 75 minutes a day of activity erased that risk. Being inactive, not the chair itself, did most of the damage.